GlobeNewswire

GridGain Cloud In-Memory-Computing-Platform-as-a-Service Adds Automatic Data Persistence, High Availability and Immediate Restarts

Share

Launch a Test Environment for Apache Ignite as an In-Memory Database with Just a Few Mouse Clicks

FOSTER CITY, Calif., Jan. 10, 2019 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced that GridGain Cloud, an in-memory-computing-platform-as-a-service (imcPaaS) solution, now includes automatic disk-based persistence of the in-memory operational dataset which ensures immediate data access if a cluster restart is ever required. Anyone interested in testing Apache Ignite as an in-memory database (IMDB) can now launch a free 4-node trial environment with just a few mouse clicks. The trial enables users to quickly and easily launch a hosted Apache Ignite in-memory database and use ANSI-99 SQL or a variety of other protocols to communicate with the cluster. GridGain Cloud is the first ACID-compliant, key-value in-memory database with ANSI-99 SQL support.

GridGain Cloud, a fully managed service that can be launched with just a few mouse clicks, delivers in-memory speed by maintaining all data in memory. GridGain Cloud offers unlimited horizontal scalability by distributing data across a distributed cluster of servers. New nodes can be added to the cluster dynamically. The data held in memory is continually backed up to disk and is available in seconds in the event of a restart. GridGain Cloud supports key-value APIs, interactive SQL with GridGain Cloud Web Console; a unified REST API for SQL and key-value operations; ANSI-99 SQL using Apache Ignite or GridGain ODBC/JDBC drivers; and Apache Ignite or GridGain thin clients for Java, .NET, C++, Python, Node.JS, PHP and other languages.

GridGain Quote
“Modern organizations need unprecedented levels of speed and scalability to support their digital transformation, omnichannel customer experience and artificial intelligence initiatives. The GridGain in-memory computing platform is quickly proving to be the most cost-effective and mature approach to achieving these goals and GridGain Cloud now shortens the learning curve to near zero,” said Nikita Ivanov, CTO of GridGain Systems.

About GridGain Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite™. GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. GridGain delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache™ Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, continuous learning and HTAP. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite and Ignite, are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)6.7.2020 08:00:00 CESTPress release

Following higher than expected effects on steatosis reduction during the Phase IIb NATIVE trial in NASH, the number of patients to be recruited in the trial evaluating lanifibranor in patients with T2DM and NAFLD has been reduced to 34 (vs. 64 initially) The Phase II trial results are expected in 2021 Daix (France), July 6, 2020 – Inventiva (Euronext: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the decision by the investigator to reduce the number of patients to be enrolled in the investigator-initiated Phase II clinical trial of lanifibranor in patients with TD2M and NAFLD being conducted by Prof. Cusi at the University of Florida. This trial aims to evaluate the metabolic effects of lanifibranor and its potential efficacy on liver triglycerides inT2DM

Dividend payment ex-date of AS “Latvijas Gāze”6.7.2020 07:45:00 CESTPress release

AS “Latvijas Gāze” (GZE1R, ISIN code LV0000100899) will close the list of shareholders for dividend payment on July 9, 2020 at the end of the working day of the Nasdaq CSD Latvian Settlement System. Proceeding from the above, the ex-date is July 8, 2020. From that date the new owner of the shares is not entitled to the dividends. AS “Latvijas Gāze” will pay dividend 0.44 EUR per share on July 10, 2020. The JSC "Latvijas Gāze" confirms that: - the profit paid in dividends was earned after January 1, 2018; - no conditions permitting the JSC "Latvijas Gāze" to reduce the corporate income tax base under Section 13 of the Corporate Income Tax Law have been applied. Additional information: Madara Ventere Head of Finance and accounting division Phone: + (371) 67 369 281 E-mail: investor.relations@lg.lv www.lg.lv

Airtel deploys India’s largest open cloud-based VoLTE network with Nokia software products6.7.2020 07:00:00 CESTPress release

Press Release FINAL Airtel deploys India’s largest open cloud-based VoLTE network with Nokia software products ·As part of its cloudification strategy, Airtel will deploy Nokia’s CloudBand Infrastructure Software 6 July 2020 Espoo, Finland – Nokia today announced that its CloudBand-based software products are powering Bharti Airtel’s (“Airtel”) Voice over LTE (VoLTE) network in India. The network supports over 110 million customers, making it the largest cloud-based VoLTE network in India and the largest Nokia-run VoLTE in the world. The cloud-based VoLTE deployment allows Airtel to provide its mobile customers faster and more reliable, cost-efficient call connectivity. The solution, which has been deployed to cover all 22 telecom service areas in India, uses Commercial Off-the-Shelf IT hardware with cloud-based Virtual Network Functions (VNFs), which consumes much less power and space compared to the traditional 2G/3G Circuit Switched legacy core. Nokia’s VoLTE solution enables Airtel

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids6.7.2020 07:00:00 CESTPress release

PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52 Results confirm linzagolix as a potential best-in-class GnRH antagonist, with a pooled responder rate of 84.7% for the 200 mg with Add Back Therapy* (ABT) dose from PRIMROSE 1 and 2 Linzagolix is the only GnRH antagonist as a potential unique treatment option for up to 50% of US women with uterine fibroids for whom ABT therapy may be contraindicated Success of PRIMROSE 1 and 2 studies enables progression towards regulatory submissions, anticipated 4Q 2020 in the EU and 1H 2021 in the US GENEVA, Switzerland and BOSTON, MA (July 6, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced top-line results from the PRIMROSE 1 and 2 studies of Ysel

Idorsia announces positive results in the second Phase 3 study of daridorexant6.7.2020 07:00:00 CESTPress release

Results confirm and reinforce the efficacy and safety profile from the first pivotal studyCompany targets filing the New Drug Application (NDA) around the end of 2020Idorsia to host an investor webcast to discuss the second Phase 3 results today at 14:00hrs CEST Allschwil, Switzerland – July 6, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia. The study confirms the findings of the first pivotal study, demonstrating efficacy of treatment with daridorexant on objective and subjective sleep parameters and showed positive effects on daytime functioning, with patients reporting no morning sleepiness and no evidence of rebound or withdrawal symptoms upon treatment discontinuation. On April 20, 2020, the company reported (media release) the results of the first pivotal study with dar

DIAC S.A.: UPDATE OF NEU MTN PROGRAMME3.7.2020 19:32:13 CESTPress release

July, 3rd 2020 DIAC S.A.: UPDATE OF NEU MTN PROGRAMME DIAC S.A. updated the Information Memorandum of its Negotiable Medium Term Notes (NEU MTN Programme). This documentation was approved by the Banque de France is available on its website under the following link: https://eucpmtn.banque-france.fr/public/#/liste-des-emetteurs/5f8b9dec-b611-ea11-80f7-001dd8b71ea9 DIAC S.A. Etablissement de crédit et intermédiaire d’assurances, au capital de 659 334 050 EUR. Siège social : 14, avenue du Pavé Neuf – 93168 Noisy-le-Grand cedex SIREN 702 002 221 RCS Bobigny – N° TVA : FR02 702002221 – Code APE 6492Z – N° ORIAS : 07 004 966 – www.orias.fr Attachment Update DIAC programme NEU MTN 2020